GoodRx (GDRX) shares soared nearly 50% on Monday after announcing a GLP-1 partnership with the Danish pharmaceutical behemoth Novo Nordisk (NVO).
In a press release this morning, the Nasdaq-listed firm said “all strengths of Ozempic and Wegovy pens are now available to eligible self-paying patients for $499-per-month through GoodRx.”
GoodRx stock has slightly outperformed in 2025, up just over 12% in the year to date.
How Novo Deal May Help GoodRx Stock
Teaming up with Novo Nordisk is a major win for GDRX shares because it positions the healthcare platform at the center of the booming GLP-1 weight-loss and diabetes drug market.
Offering Ozempic and Wegovy at a flat $499 per month to self-paying customers helps GoodRx expand access to high-demand medications while reinforcing its value proposition as a cost-saving platform.
Over time, this could drive user growth, boost engagement, and attract new pharmacy and pharma partnerships as well.
In short, with GLP-1 drugs making headlines and consumer interest soaring, GoodRx stock is now tied to one of the most lucrative trends in healthcare.
Why BofA Remains Bearish on GDRX Shares
Despite the aforementioned positives, Bank of America analyst Allen Lutz says the Novo Nordisk deal is far from a sufficient reason to load up on GoodRx shares at current levels.
In a note to clients, Lutz argued widespread pharmacy closures and changing reimbursement policy could make it difficult for GDRX stock to retain momentum in the days ahead.
On Monday, the BofA analyst maintained his “Underperform” rating and $3.40 price target on the healthcare platform, indicating potential downside of more than 30% from here.
Wall Street Disagrees with BofA on GoodRx
Investors should note, however, that Bank of America Securities is among the more bearish Wall Street firms on GoodRx stock in 2025.
According to Barchart, the consensus rating on GDRX shares remains at “Moderate Buy” with the mean target of $5.49 indicating potential “upside” of another 5% from current levels.
